Search Results

You are looking at 51 - 60 of 336 items for :

  • Refine by Access: All x
Clear All
Full access

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

combination of an epidermal growth factor receptor (EGFR) inhibitor and a vascular endothelial growth factor (VEGF) inhibitor. Case Presentation During a workup for chest pain in a 77-year-old Caucasian woman, a 3-cm liver lesion was found incidentally

Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

actionable genetic alterations: anaplastic lymphoma kinase ( ALK ) gene rearrangements and sensitizing epidermal growth factor receptor ( EGFR ) mutations. The complete version of the NCCN Guidelines addresses all aspects of management for NSCLC, including

Full access

Leora Horn

factor receptor ( EGFR ) and anaplastic lymphoma kinase ( ALK ) mutational testing is a category 1 recommendation. If the histology is squamous cell carcinoma, the NCCN Guidelines suggest that both EGFR and ALK mutational testing be considered

Full access

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen

combination with mTOR inhibitors in cancer therapy. Abbreviations: EGFR, epithelial growth factor receptor; HIF, hypoxia-inducible factors; MEK, mitogen-activated extracellular kinase; mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor

Full access

Presented by: Dara L. Aisner and Gregory J. Riely

found that the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib improved 3-year disease-free survival in stage IB–III, EGFR -positive NSCLC. 4 “This study galvanized the push for earlier testing in NSCLC,” Dr. Aisner stated. The 2021

Full access

Presented by: Gregory J. Riely

classified according to mutations and gene fusions. The guidelines highlight some key molecular subtypes that should be included in molecular testing: EGFR sensitizing mutations, ALK gene rearrangements, ROS1 rearrangements, BRAF mutations, RET

Full access

Presented by: Dustin A. Deming

molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR

Full access

Tatjana Gavrancic and Yeun-Hee Anna Park

the literature Examine the use of sorafenib in combination with platinum-based doublet chemotherapy in EGFR wild-type HAL H epatoid adenocarcinoma of the lung (HAL) is an extremely rare cancer that lacks treatment guidance and has a poor

Full access

Philip E. Lammers and Leora Horn

molecular mutation thought to drive tumor growth. 4 However, only patients with epidermal growth factor receptor (EGFR) mutations (approximately 10%-15%) or anaplastic lymphoma kinase (ALK) rearrangements (approximately 5%) have an FDA-approved therapy

Full access

Ryan D. Gentzler and Jyoti D. Patel

erlotinib and crizotinib for epidermal growth factor receptor ( EGFR )-mutated and anaplastic lymphoma kinase ( ALK )-rearranged NSCLC, respectively. This article focuses on the first-line treatment of NSCLC with no identifiable mutations with FDA